Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
University of Nevada, Reno · Sierra Eye Associates · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
304
total citations
- FWCI
- 80.17
- Percentile
- 100%
- References
- 29
Citations per year
Authors
224- AMArshad M. KhananiCorresponding
University of Nevada, Reno, Sierra Eye Associates
- SPSunil Patel
West Texas Retina Consultants
- GSGiovanni Staurenghi
University of Milan
- RTRamin Tadayoni
Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Fondation Ophtalmologique Adolphe de Rothschild
- CJCarl J. Danzig
Florida Atlantic University
Topics & keywords
Topics
Keywords
- Medicine
- Macular degeneration
- Visual acuity
- Clinical trial
- Adverse effect
- Atrophy
- Lesion
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.